Bilisensors are devices designed to measure the cumulative dose of phototherapy administered to neonates undergoing treatment for hyperbilirubinemia. The current standard of care typically involves intermittent spot measurements once a day using a handheld dosimeter that may give variable estimations. In contrast, bilisensors may enable continuous, real-time monitoring of light exposure, helping to know the total phototherapy dose received by the infant.

Inclusion Criteria:

• Participants must be admitted to the Montreal Children's Hospital (MCH) Neonatal Intensive Care Unit (NICU)
• Under phototherapy as clinically indicated
• Diagnosis of indirect hyperbilirubinemia
• Weight of >1000g at time of enrollment

Exclusion Criteria:

• Any abnormal skin conditions (example: extreme dryness, desquamation, congenital skin disorders, etc.)
• Diagnosis of direct hyperbilirubinemia
• Weight of <1000g at time of enrollment
• Any baby or family deemed ineligible (ex. too much stress, too unstable) by the clinical care team

Any micro premature, preterm or term neonate admitted to NICU undergoing phototherapy due to indirect hyperbilirubinemia will be considered for this pilot study. A convenience sample size of 6 patients will be enrolled.